# Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer

> **NCT01511536** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 38 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Cabazitaxel XRP6258
- **DRUG:** Abiraterone acetate
- **DRUG:** Prednisone 5 mg

## Key facts

- **NCT ID:** NCT01511536
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2014-07
- **Final completion:** 2014-12
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2016-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01511536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01511536, "Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01511536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*